Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7737719 | 0.86 | RAB9A (0.55) | RAB9AMEN1KMT2AITGA4ITGB7 | |
| SCHEMBL22764974 | 0.86 | TACR1 (0.53) | TACR1ALDH1A1HTR2A | |
| SCHEMBL7099710 | 0.86 | TACR1 (0.53) | TACR1ALDH1A1HTR2A | |
| SCHEMBL7099704 | 0.86 | TACR1 (0.53) | TACR1ALDH1A1HTR2A | |
| SCHEMBL6559288 | 0.82 | MMP2 (0.56) | RAB9AMAOBHTR2AITGA4ITGB7 | |
| SCHEMBL6559285 | 0.82 | MMP2 (0.56) | RAB9AMAOBHTR2AITGA4ITGB7 | |
| SCHEMBL6921335 | 0.81 | GAA (0.57) | RAB9AMAPTALDH1A1MAOBKMT2A | |
| SCHEMBL5666945 | 0.81 | MAPT (0.59) | RAB9APOLBMAPTKDM4EGLA | |
| SCHEMBL10500167 | 0.78 | IDO1 (0.54) | RAB9AALDH1A1MAOBHTR2AHTT | |
| SCHEMBL27769197 | 0.77 | IDO1 (0.50) | RAB9AMAPTALDH1A1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642355-B2 | Peptide for use in the treatment of hypertension, asthma, cerebral disorders, angina pectoris, kidney and heart disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| US-20030055213-A1 | Endothelin-antagonizing peptide | TANAKA TAKEO (JP) | 2003-03-20 | — | — | US | disclosed |
| US-6194195-B1 | PURE CULTURE; FOR PRODUCTION OF HYPOTENSIVE AGENTS AND THERAPIES FOR ASTHMA, CEREBRAL APOPLEXY, ANGINA PECTORIS, ACUTE RENAL FAILURE, CARDIAC INFARCTION, AND CEREBRAL VASOSPASM | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| EP-0698613-B1 | Endothelin-antagonizing peptide | KYOWA HAKKO KOGYO KK (JP) | 1999-03-24 | — | — | EP | disclosed |
| US-5639860-A | Endothelin-antagonizing peptide | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-06-17 | — | — | US | disclosed |
| EP-0698613-A1 | Endothelin-antagonizing peptide | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055213-A1 | Endothelin-antagonizing peptide | NPY1R, ECE1, EDNRB | RAB9A 2546/4885POLB 2897/4885MAPT 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.